{
  "docId": "019de072-1970-7036-9d15-9ffed6304914",
  "docSlug": "3db8307bc8c7b92a71fc075519a1ccaf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 35 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 35,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide categorizes the 19 abstracts into oral, mini-oral, and poster presentations, and lists three specific clinical trial highlights.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1970-7036-9d15-9ffed6304914/7",
  "deckHref": "/decks/019de072-1970-7036-9d15-9ffed6304914",
  "deckJsonHref": "/decks/019de072-1970-7036-9d15-9ffed6304914.json",
  "deckAnchorHref": "/decks/019de072-1970-7036-9d15-9ffed6304914#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.25
      },
      "kind": "list",
      "text": "Data highlights: Lynparza + abiraterone in 1st-line mCRPC PROpel Phase III trial; Lynparza + Imfinzi in 1st-line urothelial carcinoma BAYOU Phase II trial; Enhertu + nivolumab in HER2+ urothelial carcinoma U105 Phase Ib trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32054d00-cc09-49c0-bdab-2b848762d50e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "19 abstracts with three oral presentations: Two Oral presentations, One Mini-oral presentation, 16 Posters, 19 Abstracts accepted",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99d127fb-9815-4e0d-bd9a-b9633142a251",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: ASCO GU 2022 accepted abstracts. Inclusive of externally sponsored research and partner-led trials. mCRPC = metastatic castration resistant prostate cancer; HER2+ = human epidermal receptor 2 positive.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dce8c836-1cc8-4132-938c-40bd3d81fe46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "ASCO GU 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f3527bc-36c4-4b1f-bf38-c6d1e53c73f8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "f981a351-c496-4b0b-8d4b-7f842bdd7dd1",
      "evidence": "list/bullet: Data highlights: Lynparza + abiraterone in 1st-line mCRPC PROpel Phase III trial; Lynparza + Imfinzi in 1st-line urothelial carcinoma BAYOU Phase II trial; Enhertu + nivolumab in HER2+ urothelial carcinoma U",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 6,
      "beatId": "c9f64427-f026-45db-a377-f3d329a6fa9e",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Interest",
      "beatSlug": "aida-interest",
      "evidence": "The deck generates interest by presenting key messages and takeaways from the ASCO GU 2022 conference.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}